399 results on '"van Baal, Pieter"'
Search Results
2. Health outcomes and healthcare utilization associated with four undiagnosed chronic conditions: evidence from nationally representative survey data in Sri Lanka
3. Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs
4. Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses
5. Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries
6. Optimizing cardiovascular disease risk screening in a low-resource setting: cost-effectiveness of program modifications in Sri Lanka modelled with nationally representative survey data
7. The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice
8. Health outcomes in Bulgaria: Simulated effects of obesogenic environmental changes in adulthood versus childhood
9. Cost‐effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS‐HF system) in chronic heart failure in the Netherlands
10. Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands
11. The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS
12. Ranking Age-at-Death Distributions Using Dominance: Robust Evaluation of United States Mortality Trends, 2006–2021.
13. Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature
14. Estimating the costs of non-medical consumption in life-years gained for economic evaluations
15. Quantifying the Health Burden of Covid-19 Using Individual Estimates of Years of Life Lost Based on Population-Wide Administrative Level Data
16. Prospective impact of tobacco eradication and overweight and obesity eradication on future morbidity and health-adjusted life expectancy : simulation study
17. Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0
18. Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales
19. Quantifying income inequality in years of life lost to COVID-19: a prediction model approach using Dutch administrative data
20. When is it too expensive? Cost-effectiveness thresholds and health care decision-making
21. Future unrelated medical costs need to be considered in cost effectiveness analysis
22. Health care input constraints and cost effectiveness analysis decision rules
23. Future Costs in Cost-Effectiveness Analyses: Past, Present, Future
24. Health losses at the end of life: a Bayesian mixed beta regression approach
25. The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?
26. Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone
27. Health Outcomes in Bulgaria: Simulated Effects of Obesogenic Environmental Changes in Adulthood Versus Childhood
28. Forecasting differences in life expectancy by education
29. Did the health of the Dutch population improve between 2001 and 2008? Investigating age- and gender-specific trends in quality of life
30. Trends in Dutch hospital spending by age and disease 1994–2010
31. Estimating Quality of Life Decrements in Oncology Using Time to Death
32. Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries
33. Should cost effectiveness analyses for NICE always consider future unrelated medical costs?: Head to Head
34. Value of Information Analysis from a Societal Perspective: A Case Study in Prevention of Major Depression
35. A new prevention paradox: The trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers
36. Modeling and Forecasting Health Expectancy: Theoretical Framework and Application
37. The DYNAMO-HIA Model: An Efficient Implementation of a Risk Factor/Chronic Disease Markov Model for Use in Health Impact Assessment (HIA)
38. Time to death and the forecasting of macro-level health care expenditures: Some further considerations
39. Forecasting Lifetime and Aggregate Long-term Care Spending: Accounting for Changing Disability Patterns
40. Lifestyle intervention: from cost savings to value for money
41. The relevance of including future health care costs in cost-effectiveness threshold calculations for for the UK NHS
42. Improving maternal and child health in Pakistan: a programme evaluation using a difference in difference analysis
43. The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS
44. The economics of improving global infectious disease surveillance
45. Probabilistic Sensitivity Analysis: Be a Bayesian
46. Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.
47. Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations
48. Cost-Effectiveness of a Low-Calorie Diet and Orlistat for Obese Persons: Modeling Long-Term Health Gains through Prevention of Obesity-Related Chronic Diseases
49. The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action
50. Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.